jCell Therapy for Retinitis Pigmentosa and Phase 2B Data

Approaches to treating retinitis pigmentosa have included prosthetic devices and gene therapy. What if there was an approach that could treat the nearly 2 million worldwide patients with disease? Anthony Joseph, MD, discusses jCell technology, which may work independently of a patient’s genetic subtype to promote photoreceptor survival in retinitis pigmentosa patients. What data from a phase 2b trial were used to evaluate the efficacy of jCell technology? How will the therapy be tested going forward? What safety concerns should clinicians be aware of? Dr. Joseph has some answers.

This editorially independent podcast is supported with advertising.